Cargando…
Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
Autores principales: | Dimosiari, Athina, Patoulias, Dimitrios, Makris, Demosthenes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075380/ https://www.ncbi.nlm.nih.gov/pubmed/37034369 http://dx.doi.org/10.31138/mjr.33.4.384 |
Ejemplares similares
-
Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023) -
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
por: Lau, Harry Cheuk-Hay, et al.
Publicado: (2022) -
Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023) -
Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
por: Dimosiari, Athina, et al.
Publicado: (2023) -
Schedule H1: Hope or hype?
por: Hazra, Avijit
Publicado: (2014)